EUVIMEDEUVIMED entdecken
Leitlinie

Surgical Aortic Valve Replacement in Patients Above the Guideline-endorsed Age Cut-off: Reasons for Surgery and Clinical Outcomes

Johannes Petersen iD, Harun Sarwari, Till Demal, Oliver Bhadra, Simon Pecha iD, Hermann Reichenspurner, Andreas Schaefer

The Thoracic and Cardiovascular Surgeon · 01.08.2026 · 74 (05) · 384-389

DOI: 10.1055/a-2724-5108 ↗

Kurz gefasst

Leitlinie in der Zeitschrift The Thoracic and Cardiovascular Surgeon, erschienen am 01.08.2026. Verfasst von Johannes Petersen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Hamburg, Germany. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Heart Valve Prosthesis Implantation, Aortic Valve. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 2017 and 2021 ESC/EACTS guidelines for the management of valvular heart disease recommend transcatheter aortic valve implantation (TAVI) as a treatment option for severe symptomatic aortic valve stenosis (AS) in patients ≥75 years of age. However, surgical aortic valve replacement (SAVR) remains a viable option for elderly patients, particularly in specific anatomical or clinical subsets. The objective of this study was to analyze indications for SAVR and postoperative outcomes in patients ≥75 years of age. Heart team protocols were reviewed to determine indications for SAVR. The adjudication of acute procedural and early clinical outcomes was conducted in accordance with the standardized VARC-3 definitions. Furthermore, cardiovascular mortality and rate of aortic valve re-intervention were assessed at latest follow-up with a median duration of 5.5 years (1.9–7.1 years). A total of 43 patients ≥75 years of age (51% male) underwent isolated SAVR at our center between 2017 and 2022. STS/EuroSCORE II was 1.7 ± 0.6%/1.7 ± 0.4%. The age distribution of patients was as follows: 75 to 76 years in 32.5% (14/43), 77 to 79 years in 46.5% (20/43), and 80 to 83 years in 21% (9/43) of patients. Indications for SAVR included low operative risk according to STS (1.6 ± 0.3%) and EuroSCORE II (1.4 ± 0.3%) in 51.2% (22/43), unicuspid/bicuspid aortic valve in 21% (9/43), patient preference in 13.9% (6/43), large aortic annulus in 9.3% (4/43), and massive calcification of the left ventricular outflow tract in 4.6% (2/43) of patients. Mean aortic cross clamp and cardiopulmonary bypass times were 67.1 ± 18.2 minutes and 98.6 ± 25.1 minutes. All-cause 30-day mortality was 0% (0/43). Technical success, device success, and early safety were 100% (43/43), 100% (43/43), and 81.4% (35/43). Bleeding complications and the need for permanent pacemaker implantation (PPM) were observed in 9.3% (4/43) and 4.6% (2/43) of patients. Mean ICU and hospital stay were 2.9 ± 2.1 days and 12.5 ± 3.6 days. Post-procedural echocardiography demonstrated absence of paravalvular leakage (PVL) in all but one patient, who exhibited moderate PVL. The mean transvalvular pressure gradient was 11.4 ± 4.5 mmHg. Latest follow-up was at median 5.5 years (1.9–7.1 years). Aortic valve re-intervention at follow-up was 2.3% (1/43) and cardiovascular mortality was 4.6% (2/43). In the current era, SAVR is rarely performed in patients ≥75 years of age. Despite the highly selective nature of the patient cohort studied, the results are excellent, with a 30-day mortality of 0% and a low cardiovascular mortality at 5 years. SAVR should still be considered a valid option in elderly patients, evaluated by a heart team, which considers each patient's unique clinical, anatomic, and procedural characteristics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Valve StenosisHeart Valve Prosthesis ImplantationAortic ValveHumansTreatment OutcomeTime FactorsRisk FactorsAgedMaleAge FactorsAged, 80 and overFemaleRisk AssessmentPostoperative ComplicationsRetrospective StudiesPatient SelectionHeart Valve ProsthesisSeverity of Illness IndexPractice Guidelines as TopicRecovery of FunctionClinical Decision-Making

Autor:innen und Institutionen

  • Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Hamburg, Germany.

ORCID-Profile: Johannes Petersen, Simon Pecha

Zitieren

APA

Petersen, J., Sarwari, H., Demal, T., Bhadra, O., Pecha, S., Reichenspurner, H., & Schaefer, A. (2026). Surgical Aortic Valve Replacement in Patients Above the Guideline-endorsed Age Cut-off: Reasons for Surgery and Clinical Outcomes. The Thoracic and Cardiovascular Surgeon, 74(05), 384-389. https://doi.org/10.1055/a-2724-5108

Vancouver

Petersen J, Sarwari H, Demal T, Bhadra O, Pecha S, Reichenspurner H, et al. Surgical Aortic Valve Replacement in Patients Above the Guideline-endorsed Age Cut-off: Reasons for Surgery and Clinical Outcomes. The Thoracic and Cardiovascular Surgeon. 2026;74(05):384-389. doi:10.1055/a-2724-5108

BibTeX
@article{Petersen2026,
  author = {Petersen, Johannes and Sarwari, Harun and Demal, Till and Bhadra, Oliver and Pecha, Simon and Reichenspurner, Hermann and Schaefer, Andreas},
  title = {Surgical Aortic Valve Replacement in Patients Above the Guideline-endorsed Age Cut-off: Reasons for Surgery and Clinical Outcomes},
  journal = {The Thoracic and Cardiovascular Surgeon},
  year = {2026},
  volume = {74},
  number = {05},
  pages = {384--389},
  doi = {10.1055/a-2724-5108}
}
Kostenlos starten →